Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Angst

Showing results (241-250 of 273) with videos related to

Pageof 28
Sort By:
International Journal of Obesity (2005)|February 24, 2006
Asthma and body weight change: a 20-year prospective community study of young adultsG Hasler, P J Gergen, V Ajdacic, et al.
Presse Medicale (Paris, France : 1983)|May 9, 2002
[Cyclothymic obsessive-compulsive disorder. Clinical characteristics of a neglected and under-recognized entity]E G Hantouche, C Demonfaucon, J Angst, et al.
Acta Psychiatrica Scandinavica. Supplementum|September 6, 2003
The Zurich Study: participation patterns and Symptom Checklist 90-R scores in six interviews, 1979-99D Eich, V Ajdacic-Gross, M Condrau, et al.
International Pharmacopsychiatry|January 1, 1977
[Comparison of the effects of pipothiazine palmitate and fluphenazine decanoate. Results of a multicenter double-blind trial]B Woggon, P Dick, H J Fleischhauer, et al.
Acta Psychiatrica Scandinavica|February 17, 2007
Parsing the clinical phenotype of depression: the need to integrate brief depressive episodesJ Angst, A Gamma, L Pezawas, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|February 1, 1997
Metabolic hyperfrontality and psychopathology in the ketamine model of psychosis using positron emission tomography (PET) and [18F]fluorodeoxyglucose (FDG)F X Vollenweider, K L Leenders, C Scharfetter, et al.
Archiv Fur Psychiatrie Und Nervenkrankheiten|September 17, 1976
[Clinical double-blind study with two different dosages of maprotiline (150 and 225 mg per day) (author's transl)]B Woggon, J Angst, M Gmuer, et al.
Pharmacopsychiatry|January 19, 2008
Determinants of voluntary vs. involuntary admission in bipolar disorder and the impact of adherenceD Schuepbach, D Novick, J M Haro, et al.
Pharmacopsychiatry|October 1, 2011
Predicting response to psychopharmacological treatment: survey of recent resultsH Stassen, I-G Anghelescu, J Angst, et al.
Comprehensive Psychiatry|July 24, 1998
The comorbidity of alcoholism with anxiety and depressive disorders in four geographic communitiesJ D Swendsen, K R Merikangas, G J Canino, et al.
Pageof 28

Showing results (241-250 of 273) with videos related to

Sort By:
Pageof 28
International Journal of Obesity (2005)|February 24, 2006
Asthma and body weight change: a 20-year prospective community study of young adultsG Hasler, P J Gergen, V Ajdacic, et al.
Presse Medicale (Paris, France : 1983)|May 9, 2002
[Cyclothymic obsessive-compulsive disorder. Clinical characteristics of a neglected and under-recognized entity]E G Hantouche, C Demonfaucon, J Angst, et al.
Acta Psychiatrica Scandinavica. Supplementum|September 6, 2003
The Zurich Study: participation patterns and Symptom Checklist 90-R scores in six interviews, 1979-99D Eich, V Ajdacic-Gross, M Condrau, et al.
International Pharmacopsychiatry|January 1, 1977
[Comparison of the effects of pipothiazine palmitate and fluphenazine decanoate. Results of a multicenter double-blind trial]B Woggon, P Dick, H J Fleischhauer, et al.
Acta Psychiatrica Scandinavica|February 17, 2007
Parsing the clinical phenotype of depression: the need to integrate brief depressive episodesJ Angst, A Gamma, L Pezawas, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|February 1, 1997
Metabolic hyperfrontality and psychopathology in the ketamine model of psychosis using positron emission tomography (PET) and [18F]fluorodeoxyglucose (FDG)F X Vollenweider, K L Leenders, C Scharfetter, et al.
Archiv Fur Psychiatrie Und Nervenkrankheiten|September 17, 1976
[Clinical double-blind study with two different dosages of maprotiline (150 and 225 mg per day) (author's transl)]B Woggon, J Angst, M Gmuer, et al.
Pharmacopsychiatry|January 19, 2008
Determinants of voluntary vs. involuntary admission in bipolar disorder and the impact of adherenceD Schuepbach, D Novick, J M Haro, et al.
Pharmacopsychiatry|October 1, 2011
Predicting response to psychopharmacological treatment: survey of recent resultsH Stassen, I-G Anghelescu, J Angst, et al.
Comprehensive Psychiatry|July 24, 1998
The comorbidity of alcoholism with anxiety and depressive disorders in four geographic communitiesJ D Swendsen, K R Merikangas, G J Canino, et al.
Pageof 28